

Kaur I, Bansal N. Effect of angiotensin receptor blocker (candesartan) on chronic fatigue syndrome in mice. *Bull. Pharm. Res.* 2016;6(3):93-104.

### References (25):

1. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. *Am. J. Hypertens.* 2000;13(1pt2):31S-38S.  
<https://www.ncbi.nlm.nih.gov/pubmed/10678286>
2. Anderson C. More indirect evidence of potential neuroprotective benefits of angiotensin receptor blockers. *J. Hypertens.* 2010;28(3):429.  
<https://www.ncbi.nlm.nih.gov/pubmed/20160578>
3. Baiardi G, Bregonzio C, Jezova M, Armando I, Saavedra JM. Angiotensin II AT1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. *Ann. N. Y. Acad. Sci.* 2004;1018:131-6.  
<https://www.ncbi.nlm.nih.gov/pubmed/15240361>
4. Bali A, Jaggi AM. Angiotensin as stress mediator: Role of its receptor and interrelationships among other stress mediators and receptors. *Pharmacol. Res.* 2013;76:49-57.  
<https://www.ncbi.nlm.nih.gov/pubmed/23892268>
5. Bregonzio C, Seltzer A, Armando I, Pavel J, Saavedra JM. Angiotensin II AT<sub>1</sub> receptor blockade selectively enhances brain AT<sub>2</sub> receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. *Stress* 2008; 11(6):457-66.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742314>
6. Dhir A, Kulkarni SK. Vanlafaxine reverses chronic fatigue-induced behavioural, biochemical and neurochemical alterations in mice. *Pharmacol. Biochem. Behav.* 2008;89(4):563-71.  
<https://www.ncbi.nlm.nih.gov/pubmed/18336891>
7. Dhir A, Naidu PS, Kulkarni SK. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. *Addict. Biol.* 2005;10(4):329-35.  
<https://www.ncbi.nlm.nih.gov/pubmed/16318954>
8. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. *Pharmacol. Rev.* 2000; 52(4):595-638.  
<https://www.ncbi.nlm.nih.gov/pubmed/11121511>

9. Ellman GL. Tissue sulfhydryl groups. *Arch. Biochem. Biophys.* 1959;82(1):70-7.  
<https://www.ncbi.nlm.nih.gov/pubmed/13650640>
10. Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S, Pütz B, Uhr M, Binder EB, Holsboer F, Keck ME. Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. *Neuropsychopharmacol.* 2006;31(11):2515-22.  
<https://www.ncbi.nlm.nih.gov/pubmed/16841071>
11. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. *Immunobiol.* 2009;214(1):33-9.  
<https://www.ncbi.nlm.nih.gov/pubmed/19159825>
12. Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: the need for subtypes. *Neuropsychol. Rev.* 2005;15(1):29-58.  
<https://www.ncbi.nlm.nih.gov/pubmed/15929497>
13. Khoury NM, Marvar PJ, Gillespie CF, Wingo A, Schwartz A, Bradley B, Kramer M, Ressler KJ. The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. *J. Clin. Psychiatry* 2012;73(6):849-55.  
<https://www.ncbi.nlm.nih.gov/pubmed/22687631>
14. Kulkarni SK, Reddy DS. Animal behavioural models for testing antianxiety agents. *Methods Find. Exp. Clin. Pharmacol.* 1996;18(3):219-30.  
<https://www.ncbi.nlm.nih.gov/pubmed/8738074>
15. Kulkarni SK. Handbook of Experimental Pharmacology. Vallabh Prakashan, Delhi: 1999; 123-5.
16. Kumar A, Garg R, Gaur V, Kumar P. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behaviour despair in mice. *Brain Res.* 2010;1311:73-80.  
<https://www.ncbi.nlm.nih.gov/pubmed/19945444>
17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal. Biochem.* 1979;95(2):351-8.  
<https://www.ncbi.nlm.nih.gov/pubmed/36810>
18. Quirin M, Pruessner JC, Kuhl J. HPA system regulation and adult attachment anxiety: individual differences in reactive and awakening cortisol. *Psychoneuroendocrinology* 2008;33(5):581-90.  
<https://www.ncbi.nlm.nih.gov/pubmed/18329180>

19. Saavedra JM, Sanchez-Lemus E, Benicky J. Blockade of brain Angiotensin II AT<sub>1</sub> receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. *Psychoneuroendocrinology* 2011; 36(1):1-18.  
<https://www.ncbi.nlm.nih.gov/pubmed/21035950>
20. Sanchez-Lemus E, Honda M, Saavedra JM. Angiotensin II AT<sub>1</sub> receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. *Behav. Brain Res.* 2012;232(1):84-92.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372928/>
21. Sanders P, Korf J. Neuro aetiology of chronic fatigue syndrome: an overview. *World J. Biol. Psychiatry* 2008;9(3):165-71.
22. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterisation of the elevated “zero maze” as an animal model of anxiety. *Psychopharmacology (Berl)* 1994;116(1):56-64.  
<https://www.ncbi.nlm.nih.gov/pubmed/7862931>
23. Srinivasan J, Suresh B, Ramanathan M. Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. *Physiol. Behav.* 2003;78(4-5):585-91.  
<https://www.ncbi.nlm.nih.gov/pubmed/12782212>
24. Wessely S. Chronic fatigue: symptom and syndrome. *Ann. Intern. Med.* 2001;134(9Pt2): 838-43.  
<https://www.ncbi.nlm.nih.gov/pubmed/11346319>
25. White PD. Chronic fatigue syndrome: Is it one discrete syndrome or many? Implications for the “one vs. many” functional somatic syndromes debate. *J. Psychosom. Res.* 2010;68(5): 455-9.  
<https://www.ncbi.nlm.nih.gov/pubmed/20403504>